Preventive strategies beyond ART will be required to end the pediatric HIV 25 epidemic. A maternal vaccine capable of boosting neutralizing antibody (nAb) 26 responses against circulating viruses in HIV-infected pregnant women could effectively 27 decrease mother-to-child transmission of HIV. However, it is not known if an HIV 28 envelope (Env) vaccine administered to infected pregnant women can enhance 29 autologous virus neutralization. were randomized to receive 300 µg Env subunit MN recombinant gp120 with alum 35 adjuvant or alum alone. AVEG 102 participants were randomized to receive 640 µg Env 36 subunit recombinant gp160 or placebo. HIV Env-specific maternal plasma binding and 37 neutralizing responses were characterized before and after vaccination in 15 AVEG 104 38 (n=10 vaccinee, n=5 placebo) and 2 AVEG 102 (n=1 vaccinee, n=1 placebo) 39 participants. Single genome amplification (SGA) was used to obtain HIV env gene 40 sequences from autologous viruses for pseudovirus production in pre-and post-41 vaccination plasma of HIV-infected pregnant vaccinees (n=6 gp120, n=1 gp160) and 42
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placebo recipients (n=3). 43
We detected an increase in MN gp120-specific IgG binding in the vaccinee group 44 between the first immunization visit and the last visit at delivery (p=0.027, 2-sided 45
Wilcoxon test). However, no difference was observed in the neutralization potency of 46 infant transmitted/founder variants, and, therefore, boosting autologous neutralizing 139 antibody responses in HIV infected pregnant women could be a viable immune strategy 140 to decrease vertical transmission. women with CD4+ T cell counts >400/mm 3 were enrolled in the second trimester of 175 healthy pregnancy and randomized to receive either 300 µg of MN rgp120 (Genentech) 176 with alum (n=17) as an adjuvant or alum with diluent (n=9) between 16 and 24 weeks of 177 gestation [24] . Booster immunizations were administered monthly, until delivery, for a 178 minimum of 3 vaccine doses and a maximum of 5 vaccine doses (Figure 1 ). Similarly, 2 179 HIV-infected pregnant women were enrolled with the same criteria in the AVEG 102 180
Protocol, though instead these women received either 640 µg of rgp160 (VaxSyn, 181
MicroGeneSys) (n=1) or a placebo (n=1). Maternal plasma samples from multiple visit 182 time points were available for 15 AVEG 104 participants (n=10 MN rgp120 vaccine, n=5 183 alum placebo) and 2 AVEG 102 participants (n=1 rgp160 vaccine, n=1 placebo) ( Table  184 1). 185
186

Ethics statement 187
Original study protocols AVEG 102 and 104 were approved by local institutional 188 review boards at the seven sites involved in the original study [24] . 5'ex/2.R3.B6R, 5min and 30s for 07For7/2.R3.B6R), followed by a final cycle of 68°C for 220 10 minutes. Then, a second round of PCR amplification was carried out with 2μl of the 221 first round product as template, 0.2μM of each primer, and the same PCR mixture as in 222 round one, in a 50μl reaction. Primer pairs for second round PCR were Env 5'in (5'-223 TTAGGCATCTCCTATGGCAGGAAGAAG-3') and Env 3'in (5'-224 GTCTCGAGATACTGCTCCCACCC-3'), Env 5'in and 2.R3.B6R (5'-TGAA 225 GCACTCAAGG CAAGCTTTATTGAGGC-3'), or Low2c (5'-226 TGAGGCTTAAGCAGTGGGT TCC-3') and VIF1 (5'-227 GGGTTTATTACAGGGACAGCAGAG-3'). Round 2 conditions were one cycle of 94°C 228 for 2 minutes, 35 cycles of 94°C for 15 seconds, 55°C for 30 seconds, and 68°C for 3 229 minutes and 30 seconds for the Env 5'in/3'in primers (4min and 30s for Env 230 5'in/2.R3.B6R, 5min and 30s for Low2c/VIF1), followed by 1 cycle of 68°C for 10 231 minutes. Round 2 PCR amplicons were visualized using precast 1% agarose E-gels 232 (Invitrogen), purified with the AMPure XP magnetic bead purification system 233 (Agencourt), and sequenced for the HIV env gene by Sanger sequencing (Table 1) . 234
235
HIV env gene genetic analysis 236
Sequences were assembled using the Sequencher program (Gene Codes) and 237 manually edited. Chromatograms were examined for sites of ambiguity, or double peaks 238 per base read, and sequences containing multiple base peaks at a single position were 239 marked as such and not studied further. Envelope sequences were aligned using the 240 
TZM-bl neutralization assay 276
Neutralization of autologous pseudoviruses by maternal plasma was measured 277 using a luciferase (Luc) reporter gene assay in TZM-bl cells (catalog no. 8129; NIH 278 AIDS Reagent Program; from John Kappes and Xiaoyun Wu), as previously described 279
[28]. Before performing the assay, plasma was heat inactivated by incubating for 30 280 minutes at 56°C. Plasma samples were added at a starting dilution of 1:20 and diluted 281 threefold serially. Then, the plasma samples were incubated with virus for 1 hour at 282 37°C. TZM-bl cells were added, and the mixture was incubated for 48 hours. 283
Luminesence was then measured using the Bright-Glo luciferase reagent and Victor X3 284 (Table S1 ). The antigen-coupled beads were incubated with diluted plasma samples 298 We tested for differences in antibody binding and neutralization responses 317 between placebo and vaccinees using 2-sided Wilcoxon tests comparing the values at 318 the first visit to those at the last visit. Because time intervals between visits differed 319 across study subjects, we also tested the change per day between visits. All statistical 320 analyses and graphs were produced using R [31] . Wilcoxon test, Figure S1 ). We observed more than 3-fold increase in antibody binding 342 responses against MN gp120 in 1/11, 2/11, and 3/11 vaccinees against antigens MN 343 gp120, linear V3.B, and gp70 V1V2, respectively. No change in change in antibody 344 binding responses was observed in placebo recipients except in one against gp70 V1V2 345 (Figure 3, Figure S2) . vaccinees and placebo recipients (Figure 4C-D) . Table 1) . To characterize viral evolution between visits in study 377 participants, we measured viral diversity through the mean pairwise Hamming distance, 378 which was calculated as the number of mutations between all pairs of env sequences 379 isolated from one sample divided by the total number of bases in the alignment. The 380 changes in viral diversity between visits observed in the placebo recipients were not 381 significantly different from those observed in the vaccinees (Figure 6 ). Yet, in a per day 382 analysis of mean Hamming distance since the pre-vaccine visit, we observed a trend in 383 which vaccinees consistently demonstrated lower HIV env gene sequence diversity than 384 placebo recipients ( Figure S4 ). However, this trend did not reach significance, 385 potentially due to limited statistical power given the small sample size. were enrolled in the AVEG 102/104 studies. In the AVEG 102 protocol, women were administered 640 µg of gp160 (n=1) or placebo (n=1). In the AVEG 104 protocol, women received 300 µg of gp120 + alum (n=17) or placebo (alum + diluent) (n=9). The primary immunization was given at Visit 2, between 16-24 weeks of gestation. Monthly booster injections were subsequently given 4 weeks apart for the duration of pregnancy (Visits 3-6) for up to 5 total immunizations (median: 5; range 4-5). Visit 9 was labor and delivery. rst and isit ecific n test). 
